YS Biopharma Co., Ltd. (YS) NASDAQ
1.02
+0.09(+9.68%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.02
+0.09(+9.68%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
773
First IPO Date
August 05, 2021
| Name | Title | Pay | Year Born |
| Dave Chenn | Co-Chief Executive Officer | 0 | N/A |
| Hui Shao | Co-Chief Executive Officer, President, Chief Business Officer & Executive Director | 0 | 1968 |
| Yuan Liu | Head of Vaccine Research | 0 | 1987 |
| Zenaida Reynoso Mojares | Chief Medical Officer | 0 | 1959 |
| Gang Li | Head of Marketing & Sales | 0 | 1982 |
| Chunyuan Wu | Chief Financial Officer & Director | 0 | 1978 |
YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.